NUVB Stock Recent News

NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that taletrectinib (IBTROZI™) has been added as a Preferred Agent in the latest National Comprehensive Cancer Network® Clinical Practice Guidelines (NCCN Guidelines®) in Oncology for Non-Small Cell Lung Cancers (NSCLC), updated on June 20. Specifically, the NCCN Guidelines® now include taletrectinib (IBTROZI) as a Preferred.

LOUISVILLE, Ky., June 16, 2025 (GLOBE NEWSWIRE) -- Onco360®, the nation's leading independent Specialty Pharmacy, has been selected as a pharmacy partner by Nuvation Bio Inc. for IBTROZI™ (taletrectinib), a kinase inhibitor approved for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC)1. This indication was approved based on the Phase 2 TRUST-I and TRUST-II studies of taletrectinib that enrolled over 300 patients with ROS1-positive NSCLC.2 ,3

The U.S. Food and Drug Administration said on Wednesday it has approved Nuvation Bio's therapy for patients with a type of lung cancer.

NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that the U.S. Food and Drug Administration (FDA) has approved IBTROZI™ (taletrectinib) for the treatment of adult patients with locally advanced or metastatic ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC). IBTROZI is a highly selective, next-generation oral ROS1 tyrosine kinase inhibitor (TKI) designed to address.

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in Nuvation Bio Inc. (NYSE:NUVB – Free Report) by 54.2% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 347,806 shares of the company’s stock after buying an additional 122,187 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.10% of Nuvation Bio worth $925,000 as of its most recent filing with the SEC. Several other institutional investors and hedge funds have also recently added to or reduced their stakes in NUVB. Peapod Lane Capital LLC purchased a new stake in Nuvation Bio in the 4th quarter valued at about $1,042,000. Palumbo Wealth Management LLC increased its stake in Nuvation Bio by 297.4% in the 4th quarter. Palumbo Wealth Management LLC now owns 65,360 shares of the company’s stock valued at $174,000 after buying an additional 48,914 shares during the last quarter

NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that additional results from TRUST-I and TRUST-II, its pivotal Phase 2 clinical studies on the efficacy and safety of taletrectinib for the treatment of advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC), will be presented at the upcoming American Society of Clinical Oncology (ASCO) 2025 Annual Meeting taking.

NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that new data from a matching-adjusted indirect comparison study evaluating taletrectinib versus entrectinib in ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) will be presented in a poster session at ISPOR 2025, the Professional Society for Health Economics and Outcomes Research's annual conference, taking place M.

Nuvation Bio Inc. (NYSE:NUVB ) Q1 2025 Earnings Call May 7, 2025 4:30 PM ET Company Participants J.R. DeVita - Investor Relations David Hung - Founder, President and Chief Executive Officer Colleen Sjogren - Chief Commercial Officer Philippe Sauvage - Chief Financial Officer Conference Call Participants Gregory Renza - RBC Capital Markets Kaveri Pohlman - Clear Street Soumit Roy - Jones Research Michael Yee - Jefferies Yaron Werber - TD Cowen Operator Good afternoon and welcome to the Nuvation Bio First Quarter 2025 Financial Results and Business Update Conference Call.

Nuvation Bio Inc. (NUVB) came out with a quarterly loss of $0.16 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.07 per share a year ago.

Nuvation Bio's taletrectinib shows strong efficacy in ROS1-positive NSCLC, with a 90.1% response rate, and FDA approval is likely by June 2025. Financially robust, Nuvation Bio has over three years of cash runway and additional liquidity options to support taletrectinib's launch and ongoing research. Despite strong data, competition from Bristol Myers Squibb's repotrectinib and other ROS1 players, and market hesitancy pose challenges for taletrectinib's market penetration.